VBLT - Vascular Biogenics Ltd.
| Previous Close | 1.7200 |
| Open | 1.7000 |
| Bid | 0.8500 x 800 |
| Ask | 1.7100 x 1200 |
| Day's Range | 1.6200 - 1.7300 |
| 52 Week Range | 0.6000 - 3.1000 |
| Volume | 101,211 |
| Avg. Volume | 175,220 |
| Market Cap | 58.486M |
| Beta (3Y Monthly) | 2.29 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.3300 |
| Earnings Date | Mar 28, 2019 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 3.25 |
- Zacks•9 hours ago
Analysts Estimate Vascular Biogenics (VBLT) to Report a Decline in Earnings: What to Look Out for
Vascular Biogenics (VBLT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
- GlobeNewswire•2 days ago
VBL Presents New Data on Potential of VB-111 to Stimulate the Immune System and Drive Immune Cells to Infiltrate Tumor Microenvironment
VBL Therapeutics (Nasdaq: VBLT), today announced the presentation of human data indicating that the viral anti-cancer investigational therapy VB-111 has potential to stimulate the immune system to induce a strong and durable response against ovarian tumors. Administration of VB-111 was associated with an infiltration of immune cells within the tumor, which was followed by tumor necrosis and sustained clinical response. VBL's study entitled “VB-111, an anti-cancer gene therapy, induces immunotherapeutic effect in platinum resistant ovarian cancer” was presented last evening at the SGO 50th Annual Meeting on Women's Cancer at the Hawaii Convention Center in Honolulu, Hawaii.
- Zacks•7 days ago
Earnings Preview: Vascular Biogenics (VBLT) Q4 Earnings Expected to Decline
Vascular Biogenics (VBLT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
- GlobeNewswire•7 days ago
VBL Therapeutics to Report Fiscal Year 2018 Financial Results on March 28
TEL AVIV, Israel, March 14, 2019 -- VBL Therapeutics (Nasdaq: VBLT), a clinical-stage biotechnology company focused on the discovery, development and commercialization of.
- GlobeNewswire•10 days ago
VBL Therapeutics to Present at the Society of Gynecologic Oncology (SGO) 50th Annual Meeting on Women's Cancer on March 18
VBL Therapeutics (Nasdaq: VBLT), a clinical-stage biotechnology company focused on the discovery, development and commercialization of first-in-class treatments for cancer, today announces that the company will present data on its Phase 3 candidate VB-111, at the SGO 50th Annual Meeting on Women's Cancer, to be held March 16 - 19, 2019 at the Hawaii Convention Center in Honolulu, Hawaii. VB-111, a potential first-in-class anticancer therapeutic candidate, is the Company’s lead oncology product currently being studied in a Phase 3 trial for ovarian cancer.
- GlobeNewswire•23 days ago
VBL Presents New Data on the Potential of its Novel VB-600 Platform for Nonalcoholic Steatohepatitis (NASH) and Rheumatoid Arthritis (RA)
VBL Therapeutics (Nasdaq: VBLT), (the “Company”) today announced new data implicating the potential of its VB-600 platform of antibodies targeting MOSPD2 (motile sperm domain-containing protein 2) for treatment of various inflammatory indications, including NASH and RA. Monocytes are immune cells that play a pivotal role in the induction and progression of various inflammatory diseases.
- GlobeNewswire•29 days ago
VBL Therapeutics Awarded $2.9 Million Non-Dilutive Grant by the Israel Innovation Authority
VBL Therapeutics (VBLT) (the “Company”) today announced that it has been awarded a non-dilutive grant of over 10 million New Israeli Shekels (approximately $2.9 million) by the Israel Innovation Authority (IIA) for 2019. The funds will support the continued development of the Company’s lead product candidate, VB-111, a first-in-class targeted anti-cancer gene-therapy agent. The Company is currently evaluating VB-111 in a potential registration study (OVAL) for the treatment of platinum-resistant ovarian cancer, with further plans to study VB-111 in additional solid tumor indications. "We are appreciative of the continued substantial support by the IIA of our VB-111 program, which is a vote of confidence in our lead product candidate and its clinical and market potential,” said Prof. Dror Harats, Chief Executive Officer of VBL Therapeutics.
- GlobeNewswire•last month
VBL Therapeutics to Present Data on its Novel VB-600 Platform at Keystone Conference on February 26
VBL Therapeutics (Nasdaq: VBLT), today announces that the Company will present new data on the potential of its VB-600 platform targeting MOSPD2 for inflammatory and oncology indications, at the Keystone Symposia on Myeloid Cells, to be held February 24—28, 2019 at the Eldorado Hotel & Spa in Santa Fe, New Mexico.
- Simply Wall St.•3 months ago
Read This Before Selling Vascular Biogenics Ltd. (NASDAQ:VBLT) Shares
It is not uncommon to see companies perform well in the years after insiders buy shares. On the other hand, we'd be remiss not to mention that insider sales have Read More...
- Thomson Reuters StreetEvents•4 months ago
Edited Transcript of VBLT earnings conference call or presentation 20-Nov-18 1:30pm GMT
Q3 2018 Vascular Biogenics Ltd Earnings Call
- GlobeNewswire•4 months ago
VBL Therapeutics to Present at the Piper Jaffray 30th Annual Healthcare Conference on November 28
VBL Therapeutics (VBLT), a clinical-stage biotechnology company focused on the discovery, development and commercialization of first-in-class treatments for cancer, today announces it will provide a corporate update, in a Fireside Chat format, at the Piper Jaffray 30th Annual Healthcare Conference, to be held at the Lotte New York Palace on November 27–29, 2017, in New York City. Vascular Biogenics Ltd., operating as VBL Therapeutics, is a clinical stage biopharmaceutical company focused on the discovery, development and commercialization of first-in-class treatments for cancer.
- Zacks•4 months ago
Vascular Biogenics (VBLT) Reports Q3 Loss, Lags Revenue Estimates
Vascular Biogenics (VBLT) delivered earnings and revenue surprises of -25.00% and -66.33%, respectively, for the quarter ended September 2018. Do the numbers hold clues to what lies ahead for the stock?
- Associated Press•4 months ago
Vascular Biogenics: 3Q Earnings Snapshot
On a per-share basis, the Modi'In, Israel-based company said it had a loss of 15 cents. The gene therapy biotech company posted revenue of $101,000 in the period. The company's shares closed at $1.12. ...
- GlobeNewswire•4 months ago
VBL Therapeutics Announces Third Quarter 2018 Financial Results
TEL AVIV, Israel, Nov. 20, 2018 -- VBL Therapeutics (Nasdaq: VBLT) today announced financial results for the third quarter ended September 30, 2018 and provided a corporate.
- GlobeNewswire•4 months ago
VBL Therapeutics Presents Results from Phase 3 GLOBE Study in Patients with Recurrent Glioblastoma at the 2018 Society for Neuro-Oncology Annual Meeting
VBL Therapeutics (VBLT), is reporting results today from its Phase 3 GLOBE study in patients with recurrent glioblastoma (rGBM) which was designed to evaluate VB-111 in combination with bevacizumab (Avastin®) (`treatment arm`), compared to bevacizumab (`control arm`). In March 2018, VBL announced top-line data for the study, which did not demonstrate a benefit in overall survival (OS) or progression-free survival for the treatment arm relative to the bevacizumab control. The GLOBE data are being presented today at the 2018 Society for Neuro-Oncology Annual Meeting by Dr. Timothy Cloughesy, MD, Professor of Clinical Neurology and Director of the Neuro-Oncology Program, UCLA School of Medicine and principal investigator of the GLOBE trial. The data include further analyses of the GLOBE data including baseline prognostic factors and subgroups analysis.
- GlobeNewswire•4 months ago
VBL Therapeutics to Report Third Quarter 2018 Financial Results on November 20
TEL AVIV, Israel, Nov. 13, 2018 -- VBL Therapeutics (Nasdaq: VBLT), a clinical-stage biotechnology company focused on the discovery, development and commercialization of.
- Thomson Reuters StreetEvents•7 months ago
Edited Transcript of VBLT earnings conference call or presentation 16-Aug-18 12:30pm GMT
Q2 2018 Vascular Biogenics Ltd Earnings Call
- Benzinga•7 months ago
The Daily Biotech Pulse: No Anxiety For Biohaven, Strongbridge's About-Face, Bristol-Myers Squibb's FDA Wait
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling the Peaks (Stocks hitting 52-week highs on Aug. 15) Inspire Medical Systems Inc (NYSE: INSP ) Merck & Co., Inc. ...
- Zacks•7 months ago
Vascular Biogenics (VBLT) Reports Q2 Loss, Lags Revenue Estimates
Vascular Biogenics (VBLT) delivered earnings and revenue surprises of 27.78% and -40.00%, respectively, for the quarter ended June 2018. Do the numbers hold clues to what lies ahead for the stock?
- Associated Press•7 months ago
Vascular Biogenics: 2Q Earnings Snapshot
On a per-share basis, the Modi'In, Israel-based company said it had a loss of 13 cents. The gene therapy biotech company posted revenue of $180,000 in the period. The company's shares closed at $1.65. ...
